Drugs Generic: Mylan Inc (NASDAQ:MYL), Zoetis Inc (NYSE:ZTS), Actavis plc (NYSE:ACT), Mallinckrodt PLC (NYSE:MNK)

Trade-Ideas LLC identified Mylan Inc (NASDAQ:MYL) as an unusual social activity candidate. MYL has more that 20x the normal benchmarked social activity for this time of the day compared to its average of 2.07 mentions/day. Mylan Inc (NASDAQ:MYL) stock performance was 1.17% in last session and finished the day at $52.63. Traded volume was 7.39million shares in the last session and the average volume of the stock remained 4.11million shares. The beta of the stock remained 1.00. Mylan Inc (NASDAQ:MYL) insider ownership is 0.60%.

Veterinary drug manufacturer Zoetis Inc. (NYSE:ZTS), which manufactures animal vaccines in Lincoln, announced in February it is partnering with Iowa State University to identify and test a vaccine. Zoetis Inc (NYSE:ZTS) rose 0.58 percent to $29.42 Friday on volume of 4.02million shares. The intra-day range of the stock was $29.23 to $29.82. Zoetis Inc (NYSE:ZTS) has a market capitalization of $14.71 billion.

Generic drug makers, Actavis plc (NYSE:ACT) and Mylan Inc. ( MYL ), are gearing up to launch their generic versions of Pfizer’s ( PFE ) Celebrex (celecoxib). Actavis plc (NYSE:ACT)’s stock on Mar 14, 2014 reported a increase of 1.72% to the closing price of $214.52. Its fifty two weeks range is $89.20-$230.77. The total market capitalization recorded $28.42billion. The overall volume in the last trading session was 2.17million shares. In its share capital, ACT has 132.50million outstanding shares.

Depomed Inc (NASDAQ:DEPO) is a specialty pharmaceutical company. The company licenses out its drug technologies and collects royalties on the same. The company is now set to receive $10 million after the U.S. Food and Drug Administration approved a drug developed by Mallinckrodt PLC (NYSE:MNK) using its technology. The drug is target at pain treatment. On Friday, shares of Mallinckrodt PLC (NYSE:MNK) advanced 4.35% to close the day at $70.01. Company return on investment (ROI) is 3.50% and its monthly performance is recorded as 5.71%. Mallinckrodt PLC (NYSE:MNK) quarterly revenue growth is 35.02%.